Related Experiment Video
Updated: Jun 21, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Differential effects of adenosine antagonists in two models of parkinsonian tremor
1California State University-Fullerton, Fullerton, CA 92834, USA. jtrevitt@fullerton.edu
Abstract:
Adenosine A(1) and A(2A) receptors are colocalized with dopamine D(1) and D(2) receptors on striatal projection neurons and adenosine antagonists have been proposed as adjunctive therapies to l-DOPA treatment in Parkinson patients. We present here two studies examining the effects of selective and non-selective adenosine antagonists in two rodent models of parkinsonian tremor. Tremulous jaw movements (TJMs) were induced by either the dopamine antagonist pimozide (1.0 mg/kg) or the acetylcholine agonist tacrine (5.0 mg/kg), and were quantified by a trained observer who was blind to the treatment conditions. Animals were treated concomitantly with either caffeine (10.0 mg/kg non-selective adenosine antagonist), 8-cyclopentyltheophylline (CPT; 10.0 mg/kg; selective A(1) antagonist) or SCH58261 (8.0 mg/kg; selective A(2A) antagonist). Caffeine, CPT and SCH58261 all significantly reduced pimozide-induced TJM activity. Surprisingly administration of adenosine antagonists did not reduce tacrine-induced TJMs, and in the case of SCH58261 significantly increased TJMs compared to tacrine alone. These results indicate that antagonism at A(1) receptors may be more important for the reduction of tremor than previously supposed. Furthermore they indicate that dopamine antagonist-induced tremor models and acetylcholine agonist-induced tremor models are not entirely similar, and caution should be taken when using these models to evaluate novel therapeutics.
More Related Videos
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers

